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Abstract
Background: Saffron is the dried stigma of Crocus sativus L. flower which commonly used as a natural remedy to
enhance health and even fights disease in the Middle-East and Southeast Asian countries.
Methods: This study was aimed to investigate protective effect of saffron extract and crocin in fatty liver tissue
of high-fat diet induced obese rats. A total of 36 healthy male Sprague Dawley rats were divided into six groups.
Two groups served as controls, a normal diet (ND) and a high-fat diet (HFD). The other four groups were each
supplemented with saffron extract and crocin at concentrations of 40 and 80 mg/kg body weight/day for 8 weeks.
All groups except ND were fed with HFD until end of the study. At baseline, blood sample was collected for
determination of levels of hepatic marker enzymes, including aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatise and albumin. Liver sample was collected, weighed and stained with haematoxylin and eosin
for further histopathological examination.
Results: Saffron extract and crocin at concentrations of 40 and 80 mg/kg had dose-dependently alleviated levels of
liver enzymes and histopathological changes in diet-induced obese rat model compared to control (HFD group).
Conclusion: This study suggested that saffron extract and crocin supplements have hepatoprotective effect against
non-alcoholic fatty liver disease and HFD-induced liver damage.
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Background
Overweight and obesity are major risk factors for med-
ical health problems, such as type 2 diabetes mellitus
(T2DM), coronary heart disease (CHD), sleep apnea,
cancer and liver disease. Nonalcoholic fatty liver disease
(NAFLD) is one of the liver diseases that commonly
affect overweight and obese individuals. NAFLD is char-
acterised by abnormal retention of triacylglycerols within
liver cell (i.e., hepatocellular steatosis) and the condition
can be advanced into more severe liver diseases, such as
non-alcoholic steatohepatitis, liver fibrosis, cirrhosis, and
not often, liver carcinoma [1]. NAFLD becomes a critical
public health issue given its high incidence, likely pro-
gression to chronic liver disease, and link with severe
cardiometabolic disorders including T2DM and CHD
[2]. Noteworthy studies have been engaged in under-
standing the pathogenesis of NAFLD and designing
therapeutic approaches.
Although there is no proven therapy for NAFLD,
weight loss and monitoring of the possibly related dis-
eases, such as diabetes mellitus and hyperlipidaemia, are
suggested. Two human studies revealed that a moderate,
persistent and steady weight loss may lead to an im-
provement of liver biochemical and histopathological
profiles [3, 4]. Since hypertriglyceridaemia and insulin
resistance are connected with NAFLD, the lipid-
lowering drug that enhances insulin resistance com-
monly reduced hepatic steatosis [5]. Also, antioxidants
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have critical roles in prevention of diseases, but still
need in-depth investigations [6].
Stigma of Crocus sativus flower, also known as saffron,
has been utilised as functional food in prevention of dis-
eases. Biological and pharmacological properties of saf-
fron and its active constituent, and their possible
therapeutic uses for a broad range of diseases have been
extensively examined [7]. Saffron extract (80 mg/kg body
weight) improved atherogenic index (lower LDL/HDL
level) and significantly reduced plasma total choles-
terol level compared to control [8]. Besides, weak to
moderate antinociceptive and anti-inflammatory ef-
fects of saffron extract were determined based on
the chronic inflammation animal model (Wistar rats)
that were induced edema by formalin in the rat's
paw, where 0.8 g/kg body weight of saffron aqueous
extract was injected to the experimental rats [9].
Safranal and crocin are the main bioactives in saffron.
Previous study reported that safranal significantly in-
creased liver antioxidant enzymes (superoxide dismutase
and glutathione S-transferase) of male aged Wistar rats
(10 and 20 months old) after supplementation of safra-
nal (0.5 μg/g body weight) for a month [10]. Crocin is
also one of the medicinal compounds of saffron besides
safranal. It has been studied for weight loss [11], inhib-
ited oxidative stress [12, 13] as well as improved insulin
resistance and blood glucose level [14–16].
Crocin supplementation (80 mg/kg body weight)
promoted weight loss by decreasing the rate of body
weight gain as well as reduce body fat, plasma triacyl-
glycerol and total cholesterol levels of male Sprague
Dawley that fed with a high-fat diet (HFD) for
12 weeks to induce obesity [7]. These beneficial ef-
fects of crocin provide a rationale for its use in indi-
vidual with NAFLD. Due to saffron extract has
medicinal effect against several diseases, therefore, we
performed selected biochemical analyses and histo-
pathological assay for determining protective effects
of crocin-rich saffron extract and crocin supplementa-
tion on NAFLD in HFD-induced obese rats. Plasma
levels of aspartate transaminase (AST), alanine trans-
aminase (ALT), alkaline phosphatase (ALP) and albu-
min (ALB) were also determined to test hepatic
function of the HFD fed rats.
Methods
Plant materials
Saffron (stigma of C. sativus flower) used in this
study was from Iranian origin. It was purchased from
a local retailer in Mashhad, Iran. The crocin powder
was purchased from Sigma-Aldrich (M) Sdn Bhd
(Selangor, Malaysia). This plant had been identified by
Ms Molaei from Ferdowsi University. The voucher
sample was kept in a reference herbarium at the
Faculty of Pharmacy, Mashhad University of Medical
Sciences, and the voucher specimen number is 134–
0319–1.
Preparation and quantification of crude extract
Preparation and quantification of a crude ethanolic ex-
tract of saffron were done according to our previously
published method [8]. Presence of crocins including
alpha-crocin, crocin 2, crocin 3, crocin 4, crocin 5 and
crocin 6 was detected at 440 nm, and safranal was deter-
mined at 308 nm in the extract. The saffron extract used
in this study contained total crocin of 29 g/100 g DW
(dry weight) and safranal of 1.9 g/100 g DW [8]. It was
estimated that high dose (80 mg/kg) and low dose
(40 mg/kg) of saffron extract supplementation groups
received daily 23.2 and 11.6 mg of crocin per kg body
weight, respectively.
Animals and diet
Animal experimental procedures were approved by
the Institutional Animal Care and Use Committee of
Universiti Putra Malaysia. Study was conducted fol-
lowing the international principles for laboratory ani-
mal use and care. A total of 36 healthy male Sprague
Dawley rats at 8 weeks old, weighed 200–250 g were
used in this survey. Each experimental group con-
sisted six rats, where all the rats were purchased from
the Faculty of Veterinary Medicine, Universiti Putra
Malaysia. Each rat was housed and acclimatised in a
temperature controlled room of 25 °C in individual
cage, and on a 12:12-h dark–light cycle. The bedding
of each cage was changed every 3 days and all rats
were given tap water ad libitum. All experimental rats
were fed with normal (5 % fat) and high-fat (40 %
fat) diets to induce obesity. Ingredients of the rat di-
ets are shown in Table 1. After obesity induction, the
rats were randomly allocated into control and treat-
ment groups as follows:
Table 1 Formulations of normal and high-fat diets
Ingredient Normal diet (g/kg diet) High-fat diet (g/kg diet)
Corn starch 650 150
Casein 200 200
Beef tallow 0 400
Corn oil 50 0
Sucrose 0 150
Cellulose 50 50
Mineral mix 35 35
Vitamin mix 10 10
DL-Methionine 3 3
Choline bitarate 2 2





(3)High-fat diet + crocin 40 mg/kg (HFD + L-CRO)
(4)High-fat diet + crocin 80 mg/kg (HFD +H-CRO)
(5)High-fat diet + saffron extract 40 mg/kg (HFD + L-
SAF)
(6)High-fat diet + saffron extract 80 mg/kg (HFD +H-
SAF)
Normal and high-fat diets were given to control rats
without addition of saffron extract and crocin, whereas
treatment groups were fed with specially prepared pellet
added with saffron extract or crocin. The saffron extract
and crocin of two different doses (40 & 80 mg/kg/day)
were supplemented to the rats by homogeneously mix-
ing the extract or crocin to the dough of HFD. The
dough was shaped, dried and stored in the dard room
before feeding the experimental rats.
Food intake
Amount of food consumed daily was measured for all
control and treatment groups from the quantity of feed
supply and the amount remaining by end of each experi-
mental day.
Blood collection and organ preparation
At the end of experimental period, the rats were fasted
overnight (12 h) and then sacrificed after ether anaesthe-
sia. Blood was collected into dry clean centrifuge tubes
and plasma was separated by centrifuging at 3000 rpm
for 15 min. Plasma samples were kept frozen for bio-
chemical analyses. The rats were thereafter quickly sacri-
ficed and livers were collected, dried on tissue and
individually weighed for each rat.
Relative liver weight
Throughout the experiment, body weight of all experi-
mental rats was recorded weekly. At the end of the
experiment, body weight and liver weight of all rats from
control and treated groups were measured and recorded.
Relative liver weight was calculated using following
equation:
Relative liver weight ¼ Absolute liver weight ðgÞ
Body weight of rat on sacrif ice day ðgÞ  100
Biochemical analysis
After 8 weeks of treatment with saffron extract and cro-
cin, plasma of the experimental rats was further tested
for selected biochemical parameters. In this study,
hepatic function of the experimental rats was evalu-
ated based on plasma levels of aspartate transaminase
(AST), alanine transaminase (ALT), alkaline phosphat-
ase (ALP) and albumin (ALB) which were determined
by colorimetric assay using COBAS C 311 Analyzer
by Roche Diagnostics (Basel, Switzerland).
Histopathological analysis
Pieces of tissue samples from right lobe of liver taken
from each rat were fixed in 10 % buffered formalin, rou-
tinely administered and fixed in paraffin wax. Embedded
paraffin sections (5 μm) were then cut and stained with
haematoxylin and eosin (H&E). For each rat, five slides
were examined using a light microscope. Quantitative
assessments of liver samples were done using validated
scoring systems for NAFLD [17], where the scoring sys-
tems are shown in Table 2.
Statistical analysis
Data were presented as mean ± standard error of the
mean (SEM). One-way analysis of variance coupled
with Duncan’s multiple range test was used to deter-
mine statistical differences between the mean values
using SPSS statistical software version 16. P values
of less than 0.05 were considered statistically signifi-
cant (p < 0.05).
Table 2 Histopathological scoring system for nonalcoholic fatty
liver disease (NAFLD) [17]
Component Grade 0 Grade 1 Grade 2 Grade 3 Range
Steatosis <5 % 5–33 % 34–66 % >67 % 0–3
Hepatocyte
ballooning
0 Few Many N/A 0–2
Lobular
inflammation
0 <2 foci/ 20× 2–4 >4 0–3
NAFLD activity
score (NAS)
– – – – 0–8
Table 3 Effect of saffron extract and crocin on relative organs
weight of rats
Groups Absolute liver weight Relative liver weight
ND 9.58 ± 0.71 2.28 ± 0.19
HFD 17.58 ± 1.21 3.07 ± 0.32# #
HFD + L-CRO 16.28 ± 3.48 2.75 ± 0.23
HFD + H-CRO 16.46 ± 3.67 3.03 ± 0.23
HFD + L-SAF 15.42 ± 3.64 2.75 ± 0.28
HFD + H-SAF 13.74 ± 2.48 2.46 ± 0.25**
Values are expressed as mean ± SEM of six rats
*p < 0.05, **p < 0.01 for negative control (HFD)
#p < 0.05, # #p < 0.01 for normal control (ND)
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Results
Relative liver weight of rats and food intake
Absolute liver weight, as well as relative liver weight
of experimental rats, were calculated (Table 3). The
relative liver weights between ND and HFD control
groups were significantly different (p < 0.01). Saffron
extract (80 mg/kg) was found to reduce the liver
weight of HFD-induced obese rats. Although the re-
sult revealed that liver weight was not adversely af-
fected by crocin treatment, high-dose crocin (80 mg/
kg/day) treated group had a slight increment of
relative liver weight. Food intakes during 8 weeks




ND HFD HFD + L-CRO HFD + H-CRO HFD + L-SAF HFD + H-SAF
0 132.4 ± 2.8 115.6 ± 9.5 106.8 ± 7.8 114.2 ± 4.6 111.3 ± 16.2 114.5 ± 13.7
1 135.1 ± 3.4 106.1 ± 8.2 94.8 ± 12.7 97.6 ± 9.7 101.5 ± 11.7 96.3 ± 14.4
2 135.1 ± 6.1 112.6 ± 4.6 105.6 ± 19.3 105.6 ± 19.3 103.8 ± 13.3 106.6 ± 8.8
3 133.2 ± 3.4 112.4 ± 7.2 105.1 ± 14.4 94.6 ± 5.4 100.3 ± 12.6 99.6 ± 5.5
4 130.1 ± 7.4 110.7 ± 5.5 112.1 ± 12.3 110.8 ± 16.3 109.3 ± 11.7 109.0 ± 9.5
5 132.7 ± 0.9 111.4 ± 6.4 110.7 ± 12.5 100.1 ± 6.6 103.1 ± 14.4 104.4 ± 2.1
6 125.1 ± 11.5 102.1 ± 9.9 98.3 ± 13.4 93.5 ± 7.1 96.6 ± 14.9 87.6 ± 4.7
7 127.6 ± 11.3 109.8 ± 17.9 106.8 ± 4.5 110.1 ± 10.2 100.5 ± 11.5 100.8 ± 5.8
8 132.3 ± 9.1 120.1 ± 3.6 104.7 ± 0.5 103.6 ± 3.5 103.5 ± 6.1 100.5 ± 1.1*
Values are expressed as mean ± SEM of six rats
*p < 0.01 for negative control (HFD)
Fig. 1 Effect of saffron extract and crocin on plasma biochemical analyses. a Aspartate transaminase (AST); b alanine transaminase (ALT); c alkaline
phosphatase (ALP); d albumin (ALB). Values are expressed as mean ± SEM (n = 6); *p < 0.05 and **p < 0.01 for high-fat diet control (HFD); #p < 0.05
and ##p < 0.01 for normal control (ND)
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treatment of experimental rats are summarised in
Table 4.
Biochemical analysis
Changes in liver enzymes of obese male rats supplemented
with saffron extract and crocin at low and high doses (40
and 80 mg/kg) are indicated in Fig. 1. Results show that
there were significantly changed for AST, ALT and ALP
(p > 0.01), as well as ALB (p > 0.05) between normal and
HFD control groups. Oral administration of saffron extract
at a high concentration (80 mg/kg) for 8 weeks showed sig-
nificant reductions in ALT, AST and ALP levels, whereas
crocin (80 mg/kg) group had a significant decrease in ALT
compared to HFD control group. Moreover, saffron extract
significantly improved level of ALB of the obese rats com-
pared to HFD control rats (p > 0.05) (Fig. 1).
Histopathological analyses
Histopathological examination of NAFLD was typically
presented by steatosis, hepatocyte ballooning, portal and
Fig. 2 Effect of saffron extract and crocin on liver steatosis based on histopathological examination (H&E staining). Representative histopathological
examination of H&E staining of liver tissue prepared from experimental rats fed with a normal diet (ND), b high-fat diet (HFD), c high-fat diet + crocin
40 mg/kg (HFD + L-CRO), d high-fat diet + crocin 80 mg/kg (HFD + H-CRO), e high-fat diet + saffron extract 40 mg/kg (HFD+ L-SAF), and
f high-fat diet + saffron extract 80 mg/kg (HFD + H-SAF) (magnification 400×). Major histopathological changes induced by HFD in rat liver
were hepatosteatosis, ballooning and inflammation of hepatocytes
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lobular inflammation. Micrographs in Fig. 2a, f show
normal hepatic structure and micrographs in Fig. 2b-e
reveal the fibrosis and steatosis of hepatocytes of obese
rats fed with HDF.
As shown in Fig. 2, micrograph (b) shows severe hepa-
tosteatosis condition of the experimental rats fed with
HDF, where many hepatocytes in acinar zone III had
ballooning and a mix inflammatory cell infiltration;
micrograph (c) reveals a mild microvascular steatosis of
liver tissues of the obese rats treated with crocin, where
lobular inflammation and hepatocellular ballooning can
be observed, whereas micrograph (d) shows a severe fi-
brosis of hepatocytes with mild steatosis. Besides, micro-
graph (e) shows a mild fibrosis around central vein with
no steatosis observed.
Interestingly, crocin and saffron extract supplementa-
tions were dose-dependently reduced hepatic steatosis with
minor ballooning and scattered inflammation (Fig. 2c-f).
Quantitative assessment of fatty liver tissues of the obese
rats that supplemented with saffron extract and crocin in-
dicated the hepatic steatosis and ballooning were signifi-
cantly improved, especially the high dose supplementation
of saffron extract (p < 0.01) and crocin (p < 0.05). In term
of NAFLD activity score (NAS), saffron extract had dose-
dependently improved NAS values, and 80 mg/kg of crocin
ameliorated the scores (Table 5).
Discussion
Similar to numerous human diseases, fatty liver in ro-
dents is diet-inducible [18]. HFD increases body weight
and causes diabetes in different strains of rodent [8, 19].
HFD can also increase level of liver fat and hepatic insu-
lin resistance more rapid than increment in peripheral
fat deposition [20]. Development of fatty liver induced
by HFD is associated with increases in the levels of
serum AST and ALT [9, 21].
In this study, after implementation of obesity induction
phase among experimental rats, we evaluated hepatic im-
plications of crocin and ethanolic extract of saffron at
doses of 40 and 80 mg/kg body weight that orally
administered to HFD induced obese rats based on a daily
basis for 56 days (8 weeks). Increased liver weight (Table 3),
highly elevated levels of AST and ALT (Fig. 1a-b) and the
observation obtained from microscopic examination of
liver tissue indicated that HFD caused hepatic steatosis and
injury to rats’ liver.
Result from biochemical evaluation shows that supple-
mentations of saffron extract and crocin were dose-
dependently reduced plasma ALT and AST levels of the
HFD-fed rats. It shows that saffron extract together with
crocin exerts protection against hepatic damage in HFD-
induced obese rats. A high level of plasma ALP is typic-
ally found in the animals with cholestatic liver disease
and also induced by hepatotoxic agents [22]. The signifi-
cant reduction in plasma ALP level of the saffron extract
(80 mg/kg) supplemented rats supports the non-
occurrence of cholestasis to experimental rats at the ex-
tract dose tested.
Histopathological findings of the liver samples demon-
strated protective effect of saffron extract at concentra-
tion of 80 mg/kg body weight against NAFLD. The
hepatoprotective activity of saffron against fatty liver
could be due to modulation of liver enzymes in parallel
with major normalisation of liver size and structure as
well as a distinct reduction of fatty infiltration in hepato-
cytes of the HFD induced obese rats.
Although this study is the first time evaluation of pro-
tective effect of saffron extract and its most bioactive
compound, crocin, among experimental rats with diet-
induced fatty liver, however, the relevant studies [23–26]
support the findings of this study that saffron is a poten-
tial nutraceutical for protecting liver tissue from hepatic
steatosis.
Conclusion
Saffron extract contains crocin as the main bioactive
compound. Overall biochemical and histopathological
outcomes suggest that saffron extract and crocin supple-
mentations at the tested concentrations maintained liver
function and alleviated hepatosteatosis in HFD induced
Table 5 Quantitative histopathological assessment of fatty liver tissues for rats fed with saffron extract and crocin
Groups Steatosis Ballooning Inflammation NAS
ND 0 0 0.33 ± 0.51 0.33 ± 0.51
HFD 2.66 ± 0.51# # 1.66 ± 0.51# # 1.50 ± 1.04 5.83 ± 1.47# #
HFD + L-CRO 1.66 ± 0.81 1.33 ± 0.51 1.00 ± 0.63 4.00 ± 1.41
HFD + H-CRO 1.33 ± 1.03* 0.66 ± 0.51* 1.33 ± 1.03 3.16 ± 1.32*
HFD + L-SAF 1.50 ± 0.54 0.50 ± 0.54** 0.66 ± 0.51 2.66 ± 0.81**
HFD + H-SAF 0.83 ± 0.75** 0.16 ± 0.40** 0.50 ± 0.54 1.50 ± 1.22**
For each scoring slide, a five-field randomly selection was considered
Scores are expressed as mean ± SEM of six rats
*p < 0.05, **p < 0.01 for negative control (HFD)
#p < 0.05, # #p < 0.01 for normal control (ND)
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obese rats, which are encouraging. A more definitive
evidence of the protective effects of saffron and crocin is
needed before saffron can generally be recommended
for treatment of fatty liver disease.
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